To the full analysis
Chugai Pharmaceutical stock: growth
4519.TChugai Pharmaceutical reported $7.9B in revenue for fiscal 2025, up 7.5% on the prior year, up 9.8% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
7.4%
per year from 2006 to 2025, per share 7.5%
Earnings (Annual rate)
13.6%
per year from 2006 to 2025, per share 13.7%
Free cash flow (Annual rate)
15.8%
per year from 2006 to 2025, per share 15.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.8% | 9.7% | 7.4% |
| Revenue per share | 9.8% | 9.6% | 7.5% |
| Earnings | 15.1% | 21.7% | 13.6% |
| Earnings per share | 15.1% | 21.6% | 13.7% |
| Free cash flow | 16.9% | 23.6% | 15.8% |
| Free cash flow per share | 16.8% | 23.5% | 15.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $2.05B | $241.26M | $120.68M |
| 2007 | $2.17B | $251.58M | $237.19M |
| 2008 | $2.05B | $246.59M | $88.26M |
| 2009 | $2.69B | $355.66M | $417.38M |
| 2010 | $2.38B | $260.2M | $97.79M |
| 2011 | $2.35B | $221.27M | $437.05M |
| 2012 | $2.43B | $302.73M | $390.91M |
| 2013 | $2.66B | $319.62M | $242.14M |
| 2014 | $2.9B | $320.16M | $112.21M |
| 2015 | $3.13B | $383.87M | $236.48M |
| 2016 | $3.09B | $336.56M | $14.85M |
| 2017 | $3.35B | $456.64M | $396.25M |
| 2018 | $3.64B | $580.83M | $260.01M |
| 2019 | $4.31B | $989.49M | $913.52M |
| 2020 | $4.94B | $1.35B | $901.97M |
| 2021 | $6.28B | $1.9B | $1.3B |
| 2022 | $7.91B | $2.35B | $1.09B |
| 2023 | $6.98B | $2.04B | $2.11B |
| 2024 | $7.35B | $2.43B | $2.49B |
| 2025 | $7.9B | $2.73B | $1.97B |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ¥159.23)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.